• Technology and Data
  • Front End Sales and Marketing
  • Allergy
  • HIV
  • Women's Health
  • Migraine
  • Compounding
  • Continuous Glucose Monitoring
  • Mental Health Awareness
  • Veterinary Pharmacy
  • CBD
  • Infectious Disease
  • Eye Health
  • Digestive Health
  • Biosimilars
  • Influenza
  • Shingles
  • COPD Management
  • Pediatrics
  • Generics
  • Pain Management
  • COVID-19
  • Immunization
  • Oncology
  • Anticoagulants
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Respiratory
  • Heart Health
  • Cardiovascular Clinical Consult

Manufacturer expands access to prostate drug


Do you have any prostate cancer patients whose treatments have failed? If so, there's a new option they can try. It's satraplatin, which GPC Biotech is offering under an expanded-access program. Called the Satraplatin Expanded Rapid Access (SPERA) protocol, the program offers hormone-refractory prostate cancer patients whose first-line chemotherapy has failed the investigational drug on a gratis basis. Satraplatin is a fourth-generation oral drug in the platinum family of compounds. For more information, contact 1-(800) 349-8086 or

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.